MEDIA_REFRESH_DATA
Media
U.S. News Room
Daiichi Sankyo Europe's Statement Regarding Esperion Therapeutics' Complaint
Download PDF
Industry Veteran, Dr. Mark Rutstein, Joins Daiichi Sankyo to Lead Global Oncology Clinical Development Program
Read More
Daiichi Sankyo, Inc. has taken measures to contribute to the overall effort to limit the spread of the virus that causes COVID-19.
Read More
These Daiichi Sankyo images are intended for news media use only.
Locations
People
Ken Keller
Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc. and Global Head of the Daiichi Sankyo Oncology Business
Medicines
(fam-trastuzumab deruxtecan-nxki)
See full prescribing Information, including boxed warnings and medication guide.
(ferric carboxymaltose injection)
(edoxaban) tablets
See full prescribing information including boxed warnings and medication guide
(pexidartinib)
See full prescribing information, including boxed warning regarding liver toxicity and medication guide.
(quizartinib)
See full prescribing information, including boxed warning and medication guide.
Resources to Help You Get Answers
Investor Relations:
DaiichiSankyoIR@daiichisankyo.co.jp
Or please click here to be redirected to our global IR site
Media Relations:
Oncology & RD Pipeline:
Jennifer Brennan
Office 908-992-6631
Mobile 908-900-3183
jbrennan2@dsi.com
Iron Deficiency Anemia (U.S.):
Matt Coppola
Office 908-992-7102
mcoppola@dsi.com
Corporate Communications (U.S.):
Kim Wix
Office 908-992-6633
Mobile 908-656-5447
kwix@dsi.com
You may also send an email to our general U.S. Public Affairs/Corporate Communications mailbox here: CorporateCommunications@dsi.com
To reach our communications team for Europe, please email: press@daiichi-sankyo.eu
To reach our communications team in Tokyo, please visit: https://www.daiichisankyo.com/media/
To reach Investor Relations, please email: DaiichiSankyoIR@daiichisankyo.co.jp